Karvezide (Hydrochlorothiazide, Irbesartan)

Irbesartan selectively blocks the AT1 receptors that bind angiotensin II, a potent vasoconstrictor. This inhibition prevents angiotensin‑II‑mediated narrowing of blood vessels and the release of aldosterone, leading to vasodilation, reduced sodium‑water retention, and ultimately a decrease in systemic blood pressure.

The dose of Karvezide is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted during follow‑up visits to achieve optimal blood‑pressure control.

Karvezide is classified as pregnancy category D because irbesartan may cause fetal harm, particularly in the second and third trimesters. It is generally avoided during pregnancy. Limited data are available for breastfeeding; caution is advised, and the benefits and risks should be evaluated by a healthcare professional.

To request Karvezide, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Karvezide combines an ARB (irbesartan) with a thiazide diuretic, offering a balance of vasodilation and volume reduction. Compared with alternatives such as losartan/hydrochlorothiazide, irbesartan provides a longer half‑life and may have a slightly more favorable side‑effect profile, while the diuretic component is similar across products.

Karvezide tablets should be stored at room temperature, below 25 °C, in their original packaging. Protect them from moisture, excessive heat and direct sunlight. Keep the container tightly closed and out of reach of children to maintain product stability and potency.

Karvezide is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water. Do not crush or chew the tablet unless specifically instructed by a healthcare professional.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, and angioedema. Patients should be monitored for sudden drops in blood pressure, changes in renal function, elevated serum potassium, or signs of swelling of the face, lips or throat, which require immediate medical attention.

Karvezide is contraindicated in patients with known hypersensitivity to irbesartan or hydrochlorothiazide, severe renal impairment, hyperkalemia, and in pregnant women (especially after the first trimester). Caution is also advised for individuals with hepatic disease, severe electrolyte disturbances, or those taking interacting medications without supervision.